Skip to main content
BRTX logo

BRTX

BioRestorative Therapies, Inc.
$0.40 +0.01 (+3.73%) At close · Jul 2
Market Cap
$10.19M
Shares
25,478,170

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.40 Open$0.40 Day$0.39–0.40 52W$0.16–1.89 Avg vol 30d20.6M Short int1.3M · 5.0% float · 1.0d Short vol20% Last earningsNov 12, 2025 DataJan 2020–Jul 2026 Filing10-Q · May 14
Equibles Rating blended score · not investment advice
Overall
Neutral
Technical · trend & momentum Sell
50 / 200-day cross no cross
Price vs 200-day avg −50% below
+ Price vs 50-day avg +30% above
RSI (14) 57 · neutral
MACD trend negative
52-week position 14% · near low
Sentiment · smart money Neutral
Trend (MA cross) 50d $0 › 200d $1 — 200d above 50d
Institutional flow -15% holders QoQ · +3 funds added
Insider flow No net insider activity over 90 days
+ Short interest 5.03% of float · ▼ -80.6% MoM · 1.0 days cover
Volume signal Volume near normal
Institution breadth 11 holders — near 3-yr low, contrarian setup
Fundamentals Strong
+ Revenue growth +123% Y/Y
+ Gross margin 415%, contracting
EPS growth −36% Y/Y
Free cash flow $-10.9M
+ Buyback $2.0M remaining
+ Balance sheet net cash $1.3M

Blended from price, positioning & fundamentals · daily-close · not investment advice.

Up next
FQ3-26 quarter ends
~Sep 30, 2026 Est
filed May 14, 2026

Technicals

trend & momentum for long-term holders Sell
3 · 2 · 1
50 / 200-day cross
no cross Neutral
Price vs 200-day avg
−50% below Bearish
Price vs 50-day avg
+30% above Bullish
RSI (14)
57 · neutral Neutral
MACD trend
negative Bearish
52-week position
14% · near low Bearish
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow Distributing
-15% holders QoQ · +3 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
5.03% of float · ▼ -80.6% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
11 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
52-wk low $0 Now $0 · 14% 52-wk high $2
vs 200-day avg -50% vs 50-day avg +30%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
BRTX
BioRestorative Therapies, Inc.
this stock
$10.19M -66.0% +122.8% 5.0%
AKTX
Akari Therapeutics Plc
$953.21B -9.9% 0.0%
ONC
BeOne Medicines Ltd.
$470.30B -2.0% +22179.2% 957.1 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
$134.02B +16.5% +46.2% 31.3 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
$69.80B -15.1% +20.8% 16.3 3.2%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
11
% held
2.7%
Net QoQ
+349.9K sh
Top holder
Auctus Fund Management LLC
Held Float
View
Held by Funds
Fund positions
4
View
Short & Settlement
Short Interest Falling
Shares short
1.3M
Days to cover
1.0d
Change
-5.3M sh
View
Short Volume
Short vol %
20%
As of
Jul 2, 2026
Short Total
View
Fails to Deliver
FTD shares
1
Value
$0
As of
Jun 10, 2026
View
Off-Exchange
Off-exchange %
71.1%
Week of
May 4, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$359.7K
Net income (FY)
$-14.2M
EPS diluted
$-1.58
View
Buybacks
Authorized
$2.0M
Remaining
$2.0M
Spent Remaining
View
Filings
SEC Filings
Latest
8-K
Filed
Jun 12, 2026
This year
9
View
Exempt Offerings
Offering
$1.4M
Filed
Oct 9, 2025
View
Earnings & Events
Earnings Calls
Last call
Nov 12, 2025
View

Performance

5D 20D 120D MTD YTD
BRTX +1.5% +17.9% -66.7% +6.4% -66.0%
SPY +1.4% -1.3% +8.0% -0.3% +9.2%
vs SPY +0.1% +19.1% -74.7% +6.7% -75.2%

Capital returns

Buyback program · as of Mar 31, 2026
Authorized
$2.00M
Spent (derived)
$0
Remaining
$2.00M
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1505497 CUSIP 090655606 Visit website Investor relations